The Health Lawyer - June 2020

    Vol. 32 No. 5  

    Health

    Guest Chair's Column: Dying to Belong: Racism as a Public Health Issue

    By Montrece M. Ransom, JD, MPH, Vice Chair, Coordinating Committee on Diversity, ABA Health Law Section

    I am obsessed with the phenomenon of belonging. For the past year, I’ve been studying, presenting workshops on, and writing about the importance of fostering a sense of belonging in all of our shared spaces. In addition, the heart of my coaching practice is affirming to my clients that anywhere they are called or aspire to be, they belong. Belonging is a basic human need.

    Featured Articles

    Health

    The Path to Successful Utilization of Alternative Payment Models

    By Todd Zigrang, MBA, MHA, FACHE, CVA, ASA and Jessica Bailey-Wheaton, Esq., Health Capital Consultants, St. Louis, MO, and Khaled Klele, Esq., Riker Danzig Scherer Hyland & Perretti LLP, Morristown, NJ

    The U.S. healthcare system is in the process of shifting from traditional fee-for-service (FFS) payment to value-based alternative payment models (APMs). The number of APMs were significantly accelerated by the Patient Protection and Affordable Care Act (PPACA), which established the Medicare Shared Savings Program (MSSP) for accountable care organizations (ACOs).

    Health

    COVID-19 and Resource Allocation: Planning for Times of Scarce Medical Resources

    By Lynn M. Barrett, Esq., CHC, CCP, Barrett Law, PA, Weston, FL

    President Theodore Roosevelt once reportedly said, “In any moment of decision, the best thing you can do is the right thing, the next best thing is the wrong thing, and the worst thing you can do is nothing.” During the COVID-19 pandemic, it has not always been easy to determine what doing the right thing means. In times when medical resources become scarce, choices may have to be made as to who should receive limited medical supplies and services.

    Health

    COVID-19 and the Pharmaceutical Industry in Singapore and Myanmar: A Comparison of Developed and Frontier Markets

    By William D. Greenlee, Jr., Esq., DFDL Asia Law Firm, Singapore

    The COVID-19 Coronavirus pandemic continues to wreak havoc and sow disruption around the world. In response, health authorities, pharmaceutical companies, life science laboratories and research centers (the “Pharmaceutical Industry”) are scrambling to develop potential treatments, viable inoculations, test kits and related products (the “Products”).